Cited by 70Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro

Open access
Ruzza, Paolo, Siligardi, Giuliano, Hussain, Rohanah, Marchiani, Anna, Islami, Mehmet, Bubacco, Luigi, Delogu, Giovanna, Fabbri, Davide +7 more·2014·ACS Chemical Neuroscience

Abstract

The β-lactam antibiotic ceftriaxone was suggested as a therapeutic agent in several neurodegenerative disorders, either for its ability to counteract glutamate-mediated toxicity, as in cerebral ischemia, or for its ability to enhance the degradation of misfolded proteins, as in Alexander's disease. Recently, the efficacy of ceftriaxone in neuroprotection of dopaminergic neurons in a rat model of Parkinson's disease was documented. However, which characteristics of ceftriaxone mediate its therapeutic effects remains unclear. Since, at the molecular level, neuronal α-synuclein inclusions and pathological α-synuclein transmission play a leading role in initiation of Parkinson-like neurodegeneration, we thought of investigating, by circular dichroism spectroscopy, the capability of ceftriaxone to interact with α-synuclein. We found that ceftriaxone binds with good affinity to α-synuclein and blocks its in vitro polymerization. Considering this finding, we also documented that ceftriaxone exerts neuroprotective action in an in vitro model of Parkinson's disease. Our data, in addition to the findings on neuroprotective activity of ceftriaxone on Parkinson-like neurodegeneration in vivo, indicates ceftriaxone as a potential agent in treatment of Parkinson's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/cn400149k

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Mandell G. L., and Sande M. A. (1990) Antimicrobial agents. In Goodman and Gilman’s The Pharmacological Basic of Therapeutics (Gilman A. G., Rall T. W., Niles A. S., and Taylor P., Eds.), pp 1085–1092, Pergamon Press, New York. [Google Scholar]

Cited by

Sorted by citations

Authors
Ruzza, P., Siligardi, G., Hussain, R., Marchiani, A., Islami, M., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sechi, M., Pala, N., Spissu, Y., Migheli, R., Serra, P. A., & Sechi, G.
Affiliations
  • National Research Council (IT)
  • Diamond Light Source (GB)
  • University of Padua (IT)
  • University of Sassari (IT)
Corresponding author
  • Ruzza, Paolo
  • Sechi, GianPietro
Venue
ACS Chemical Neuroscience
Published
2013-10-07
Volume
5
Issue
1
Pages
30-38
ISSN
1948-7193 (ISSN-L)
OpenAlex
W2035131474
Cited by
70
References
39
Citations by year
2026: 5 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 9 · 2017: 7 · 2016: 7 · 2015: 4 · 2014: 3
FWCI
2.96
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Neuroscience (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UnissResearch (Università degli Studi di Sassari) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
ceftriaxone, alpha-synuclein, protein polymerization, neuroprotection, Parkinson's disease, beta-lactam antibiotics, protein-protein binding, dopaminergic neurons, neurodegeneration, circular dichroism
MeSH terms
Animals, Ceftriaxone, Computer Simulation, Dose-Response Relationship, Drug, Flow Cytometry, Kinetics, Models, Molecular, Protein Binding, Mass Spectrometry, Time Factors, Oxidopamine, PC12 Cells, Adrenergic Agents, Neuroprotective Agents, Rats, alpha-Synuclein, Polymerization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review